Merck & Co. Wins FDA Label Update for Sotatercept in Recently Diagnosed PAH

The FDA has approved a label update for sotatercept (Winrevair) incorporating HYPERION trial data, extending the drug’s clinical evidence base to recently diagnosed pulmonary arterial hypertension patients on background therapy.

A flat editorial illustration depicting the regulatory approval pipeline for a pulmonary arterial hypertension treatment, rendered in deep navy, warm gold, and powder blue geometric forms across three compositional variants showing process, institutional actors, and human stakes respectively.

PHARMA REGULATION · RARE DISEASE LABEL UPDATE · SEPTEMBER 26, 2026 · USA

Two label updates in less than a year have added phase 3 outcomes data to a drug first approved in March 2024. The U.S. Food and Drug Administration has approved an update to the label for sotatercept (Winrevair), Merck’s activin signaling inhibitor for pulmonary arterial hypertension (PAH, World Health Organization Group 1), to include efficacy and safety data from the phase 3 HYPERION trial — a study in recently diagnosed adults that Merck stopped early based on the positive interim results of the ZENITH trial and a review of the totality of data, according to Merck.

The HYPERION trial enrolled 320 adults recently diagnosed with PAH, all on background therapy, with half receiving sotatercept and half receiving placebo, per Fierce Pharma’s reporting on the September 2025 European Respiratory Society Congress presentation. Sotatercept reduced the risk of clinical worsening events — defined as all-cause death, unplanned PAH-related hospitalizations of more than 24 hours, atrial septostomy, lung transplantation, or PAH deterioration — by 76% compared with placebo. In absolute terms, 37% of patients in the placebo arm experienced a clinically worsening event versus 11% in the sotatercept arm. More than 70% of participants were on double background therapy, and the severity of disease was World Health Organization Functional Class (FC) II or III. The trial also showed a treatment benefit as early as six weeks, with consistent effects across prespecified subgroups including people with idiopathic PAH, those with connective tissue disease, and those on both double and triple background therapy, according to Fierce Pharma.

The label update follows a prior supplemental biologics license application (sBLA) approval in October 2025, which updated the label to reflect that sotatercept lowers the risk of clinical worsening events in adults with advanced PAH, based on the earlier phase 3 ZENITH trial, according to Healio. ZENITH enrolled 172 patients at the highest mortality risk, those in FC III or IV, and achieved a 76% reduction in the risk of all-cause death, lung transplantation, and hospitalization versus placebo plus maximum background therapy, according to Fierce Pharma. Both the ZENITH and HYPERION results were published in The New England Journal of Medicine, per Fierce Pharma’s reporting.

From high-risk add-on to earlier standard of care

The clinical profile now encoded in sotatercept’s label spans the PAH severity spectrum in a way that was not possible at the drug’s initial approval in March 2024. At launch, the FDA approved sotatercept to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events, per the original BLA approval letter (BLA 761363Orig1s000). The ZENITH-based label update added outcomes data for the highest-risk patients. The HYPERION-based update now extends the evidentiary base to recently diagnosed patients at intermediate or high risk of disease progression — a population that, by definition, is earlier in the treatment journey.

Dr. Vallerie McLaughlin, quoted in Merck’s announcement, said that ‘the results of HYPERION provide evidence for the use of WINREVAIR in adults diagnosed with PAH within the previous year who were receiving background therapy.’

Payer exposure at $238,000 per patient annually

The commercial stakes are defined by a list price of $14,000 per vial, with most patients using a single vial every three weeks — translating to approximately $238,000 per year per patient, according to Reuters, citing Merck’s own pricing disclosure at the time of the March 2024 launch. The U.S. PAH population is approximately 40,000 people, according to Reuters and Fierce Pharma, both citing the same figure. No analyst peak-sales estimate has been published in the sources reviewed for this article.

Merck acquired sotatercept as the central asset of its $11.5 billion purchase of Acceleron in 2021, per Fierce Pharma. No Latin American regulatory filings or approvals — at Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA), Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), or Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) — are confirmed in the sources reviewed.

For U.S. payers, the HYPERION label update is a prompt for formulary review. The FDA updated the label to include HYPERION efficacy and safety data in recently diagnosed adults, and coverage criteria written before that update may not reflect the evidence the label now contains. Medicare and commercial payers have not publicly disclosed updated coverage policies in response to either the ZENITH or HYPERION label changes; the Centers for Medicare & Medicaid Services (CMS) has not issued a national coverage determination for sotatercept, and no such determination is confirmed as pending in the sources reviewed.

The principal friction for broader uptake is not clinical but economic. Sotatercept’s dosing regimen — a starting dose of 0.3 mg/kg by subcutaneous injection, titrated to a target dose of 0.7 mg/kg every three weeks, per the current prescribing information — requires hemoglobin and platelet monitoring before each of the first five doses, or longer if values are unstable, per FDA labeling. The monitoring burden, combined with the annual cost, means that prior authorization requirements are likely to remain stringent even with HYPERION data now in the label. Label data that support earlier use do not automatically translate into earlier payer approval of claims; the formulary update cycle and prior authorization criteria operate on their own timelines, independent of the regulatory calendar.

The safety profile carries its own complexity. The prescribing information lists erythrocytosis — which, if severe, may increase the risk of thromboembolic events and hyperviscosity syndrome — and severe thrombocytopenia as warnings requiring dose modification. Serious bleeding events were reported and were more likely with concomitant prostacyclin and/or antithrombotic agents, or with low platelet counts, per the FDA label. These monitoring requirements add clinical infrastructure costs that do not appear in the list price.

No named biosimilar applicant has been identified in the sources reviewed. Sotatercept remains the only FDA-approved activin-signaling inhibitor for PAH. No generic or biosimilar application for sotatercept appears in the FDA’s publicly available application records reviewed for this article.

What to Watch

  1. Whether CMS or major commercial payers issue updated coverage policies or prior authorization criteria reflecting the HYPERION label update
  2. Any ANVISA, COFEPRIS, or ANMAT filing or approval for sotatercept, which would open the Latin American market to the drug
  3. Merck’s disclosure of sotatercept revenue in quarterly filings, which would provide the first public sizing of the drug’s commercial trajectory against its $11.5 billion acquisition cost
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper signal in the HYPERION label update is structural: two phase 3 trials that ended early — ZENITH on positive interim results, and HYPERION on the strength of those ZENITH results and a review of the totality of data — have produced a label whose clinical data now span the PAH severity spectrum, from recently diagnosed intermediate-risk patients to those at maximum mortality risk. The evidentiary architecture is unusually complete for a drug at this stage of its commercial life — but the gap between broad label data and broad payer access is where the next two years of sotatercept’s story will be written.

Clinical Efficacy: HYPERION vs ZENITH

Trial Enrollment Relative Risk Reduction vs Placebo Event Rate (Drug)
HYPERION (clinical worsening) 320 patients 76% 11%
ZENITH (morbidity/mortality) 172 patients 76% 17%

Key Distinction: HYPERION enrolled more than 70% of patients on double background therapy, reflecting earlier-stage disease intervention.

Sources: Fierce Pharma (HYPERION: 2025-09-30; ZENITH: 2025-03-31)

Why this is relevant

Patients

Adults recently diagnosed with pulmonary arterial hypertension at intermediate or high risk of disease progression may now have a stronger clinical basis for earlier access to sotatercept, with HYPERION data showing an 11% event rate on the drug versus 37% on placebo — though payer prior authorization criteria will determine actual access timelines.

Industry

Merck’s sotatercept label now carries evidence across the PAH severity spectrum, from recently diagnosed patients to those at maximum mortality risk, a label architecture that may support positioning as a foundational therapy rather than a late-line add-on, with the $11.5 billion Acceleron acquisition cost as the commercial benchmark against which revenue will be measured.

Payers

At a list price of approximately $238,000 per patient annually, the HYPERION label update is a prompt for formulary review; coverage criteria calibrated to the original March 2024 label may not reflect the HYPERION efficacy and safety data the label now includes, and CMS has not issued a national coverage determination for sotatercept.

Litigation

No active litigation or regulatory enforcement action involving sotatercept has been identified in the sources reviewed for this article.

Sources: Merck · Healio

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related